Kosuke Shimizu Selected Research

alanyl-prolyl-arginyl-prolyl-glycine

1/2011	PET imaging of brain cancer with positron emitter-labeled liposomes.
11/2008	Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
9/2006	Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kosuke Shimizu Research Topics

Disease

32	Neoplasms (Cancer) 01/2022 - 06/2002
9	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2004
9	Brain Ischemia (Cerebral Ischemia) 12/2019 - 05/2012
8	Carcinoma (Carcinomatosis) 12/2021 - 06/2002
8	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2019 - 05/2012
6	Melanoma (Melanoma, Malignant) 01/2013 - 03/2008
5	Reperfusion Injury 12/2019 - 05/2012
5	Stroke (Strokes) 01/2017 - 05/2012
5	Ischemia 01/2017 - 02/2009
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2016
4	Ischemic Stroke 01/2017 - 11/2015
2	Low Tension Glaucoma 01/2022 - 01/2020
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 01/2017
2	Dementia (Dementias) 01/2018 - 01/2014
2	Hypersensitivity (Allergy) 01/2017 - 05/2013
2	Sarcoma (Soft Tissue Sarcoma) 01/2012 - 11/2006
1	Endocarditis 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/2022
1	Ocular Hypertension (Glaucoma, Suspect) 01/2022
1	Hemorrhage 01/2022
1	Microsatellite Instability 01/2022
1	Lymphatic Metastasis 01/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Adenocarcinoma 01/2022
1	Urinary Retention 01/2022
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2021
1	Carcinogenesis 12/2020
1	Cysts 09/2020
1	Embolism (Embolus) 01/2019
1	Atherosclerosis 01/2019
1	Atherosclerotic Plaque (Atheroma) 01/2019
1	Neuroblastoma 01/2018

Drug/Important Bio-Agent (IBA)

24	Liposomes (Liposome)IBA 10/2021 - 06/2002
10	Pharmaceutical PreparationsIBA 10/2021 - 09/2006
8	Neuroprotective AgentsIBA 01/2017 - 05/2012
7	Peptides (Polypeptides)IBA 10/2021 - 06/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 06/2002
5	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2018 - 01/2011
3	pembrolizumabIBA 01/2022 - 01/2021
3	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 03/2019
3	Proteins (Proteins, Gene)FDA Link 12/2020 - 08/2002
3	Small Interfering RNA (siRNA)IBA 01/2018 - 06/2012
3	nobiletinIBA 01/2018 - 01/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 01/2008
3	Therapeutic UsesIBA 01/2016 - 02/2005
3	CholesterolIBA 01/2013 - 11/2010
3	alanyl-prolyl-arginyl-prolyl-glycineIBA 01/2011 - 09/2006
2	omidenepag isopropylIBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 12/2016
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2019 - 01/2014
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 06/2012
2	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2018 - 06/2012
2	MicroRNAs (MicroRNA)IBA 12/2017 - 01/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 08/2016
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 11/2015
2	AntigensIBA 01/2017 - 05/2013
2	fasudil (AT 877)IBA 01/2017 - 06/2016
2	Drug CarriersIBA 01/2016 - 09/2006
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2016 - 04/2013
2	Triethylenephosphoramide (TEPA)IBA 01/2013 - 06/2012
2	Erythropoietin FDA Link 12/2012 - 05/2012
2	EstersIBA 01/2012 - 10/2006
2	NaphthoquinonesIBA 01/2012 - 10/2006
2	rhinacanthin-NIBA 01/2012 - 11/2006
2	TeaIBA 01/2011 - 01/2010
2	Oxygen (Dioxygen)IBA 02/2009 - 05/2004
2	dpp-cndacIBA 05/2008 - 06/2002
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 02/2005 - 05/2004
1	MucinsIBA 01/2022
1	tafluprostIBA 01/2022
1	abirateroneIBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	Docetaxel (Taxotere)FDA Link 01/2022
1	cabazitaxel FDA Link 01/2022
1	PlatinumIBA 12/2021
1	Myelin-Oligodendrocyte GlycoproteinIBA 10/2021
1	AutoantigensIBA 10/2021
1	Immunoglobulin Fab FragmentsIBA 10/2020
1	Thromboplastin (Tissue Factor)IBA 10/2020
1	solanoeclepin AIBA 09/2020
1	Pregnenolone Carbonitrile (PCN)IBA 09/2020
1	TriterpenesIBA 09/2020
1	ifenprodilIBA 12/2019
1	phosphatidylserine receptorIBA 01/2019
1	Apolipoproteins E (ApoE)IBA 01/2019
1	EnzymesIBA 01/2019
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2019
1	PhosphatidylserinesIBA 01/2019
1	Radioisotopes (Radionuclides)IBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2018

Therapy/Procedure

16	Therapeutics 01/2022 - 06/2002
8	Drug Therapy (Chemotherapy) 01/2022 - 06/2002
3	Intravenous Injections 01/2018 - 01/2010
2	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 12/2020
2	Cystectomy 01/2021 - 01/2017
2	Thrombolytic Therapy 01/2017 - 11/2015
1	Castration 01/2022
1	Transurethral Resection of Prostate (TURP) 01/2022
1	Nephrectomy 01/2022